Eli Lilly (LLY)
Salud / Farmacéutica
Leader of the GLP-1 duopoly: revenue +47%, operating margin 46%, tirzepatide patented through 2036. At ~$1,249 (EV/EBIT ~35×, the most expensive in big pharma) 5-year base ~$1,674 (+7%/year with buybacks and dividend): Fairly valued — an exceptional business at a price of perfection; the market is pricing in revenue tripling, and the base scenario (multiplying by ~2.5x, already spectacular) leaves a moderate return.
- Price
- $1,249.00
- Intrinsic value (5y, base)
- $1,674
- Total annual return (5y)
- 6.8%
- Status (nominal)
- Fairly valued
- Margin of safety
- +10%
The essentials
- Leader of the GLP-1 duopoly: Mounjaro (+99%) + Zepbound (+175%) = 56% of revenue (65% in Q1'26); combined they already exceed Novo's Ozempic+Wegovy. TTM revenue $72.2bn (+47%), operating margin ex-IPR&D 46%.
- Tirzepatide patent through 2036 (US) — an unusually long runway — and an enormous manufacturing barrier ($50bn+ invested, 10 new sites). orforglipron (oral GLP-1) approved in Apr-2026 expands the market beyond injectables.
- But the price: EV/EBIT ~35× / normalized P/E ~41× — the most expensive in all of big pharma (~2× the group). The reverse-DCF requires a near-bull scenario (revenue tripling to ~$200bn) for a 10%; the base case (multiplying by ~2.5x to ~$178bn, already spectacular) yields ~+7%.
Intrinsic value — two valuation methods
Total return at 5 years: 6.8%/year = 6.0% appreciation + 0.8% dividend. The target price ($1,674) is ex-dividend; the $54 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($1,249) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $1,249 trades ~10.1% below its value discounted to today (~$1,390); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($1,674) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$867.
Thesis
The business
Eli Lilly is the leader of the GLP-1 duopoly and one of the best businesses in pharma: revenue growing +47% (accelerating to +56% in Q1'26), operating margin ex-IPR&D of 46% (up from 27% in 2021 — extraordinary operating leverage), and a three-layer moat (tirzepatide patent through 2036, unreplicable manufacturing scale, and its own successor pipeline with oral orforglipron already approved and retatrutide in Phase 3). The quality of the business is not in question.
The valuation
A pharma is valued on EV/EBIT over normalized earnings (neutralizing volatile acquired-R&D charges), with the pipeline valued separately. At ~$1,249, Lilly trades at ~34× EV/EBIT and ~41× normalized earnings — the highest multiple in all of big pharma, ~2× the group average.
The base scenario projects revenue multiplying by ~2.5x to ~$178bn over five years (decelerating from ~+29% toward ~+13%, with the MFN pricing cut offset by volume and the oral pill), an operating margin of ~47%, and multiple compression toward ~17.5× EV/EBIT (still a premium given the patent horizon). That gives ~$1,674/share in five years → an annual return of ~+7%. The upside is bounded by multiple compression: paying ~34× today leaves little margin even with earnings multiplying by ~2.5x.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The reverse-DCF makes it explicit: to get a 10% annual return from $1,249, Lilly would need to grow EBIT to ~$99bn — essentially the bull scenario (revenue tripling to ~$200bn); for 15%, more than the bull. The market is already pricing in near-perfection. The verdict is Fairly valued: the margin of safety (price vs. value brought to today) is negative (the price exceeds the value brought to today), and both lenses —EV/EBIT and discounted cash flow— give a value today below the price. It's an exceptional business at a price that leaves no margin of safety.
What to watch
The risk isn't the business, it's the price and pricing policy. Overvaluation resolves either with time (revenue growing into the multiple over years) or with a correction. Watch: the depth of the MFN/IRA cut (how much further does the realized price compress?), competition for the next generation (Novo in orals, Amgen, Roche), the sustainability of tirzepatide/retatrutide's efficacy lead, and execution of the manufacturing expansion. The pipeline optionality (retatrutide, the deep Alzheimer's/oncology/cardio pipeline) is free upside, not in the base case — it's what could justify the price if it matures.
Educational / informational. Does not constitute investment advice.